Breaking News
Get 55% Off 0
Selloff or Market Correction? Either Way, Here's What to Do Next
See Overvalued Stocks
Close

Pictet-biotech I Dy Gbp (0P0000M0RR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
856.780 +11.130    +1.32%
20/12 - Delayed Data. Currency in GBP
Type:  Fund
Market:  Luxembourg
Issuer:  Pictet Asset Management (Europe) SA
ISIN:  LU0448836352 
Asset Class:  Equity
  • Morningstar Rating:
  • Total Assets: 1.35B
Pictet Biotech I dy GBP 856.780 +11.130 +1.32%

0P0000M0RR Historical Data

 
Get free historical data for 0P0000M0RR fund. You'll find the end of day price of the Pictet-biotech I Dy Gbp fund for the selected range of dates. The data can be viewed in daily, weekly or monthly time intervals. At the bottom of the table you'll find the data summary for the selected range of dates.
Time Frame:
11/25/2024 - 12/23/2024
 
Date Price Open High Low Change %
Dec 20, 2024 856.780 856.780 856.780 856.780 1.32%
Dec 19, 2024 845.650 845.650 845.650 845.650 -4.66%
Dec 18, 2024 887.000 887.000 887.000 887.000 -0.20%
Dec 17, 2024 888.810 888.810 888.810 888.810 -0.03%
Dec 16, 2024 889.090 889.090 889.090 889.090 1.32%
Dec 13, 2024 877.520 877.520 877.520 877.520 -1.70%
Dec 12, 2024 892.720 892.720 892.720 892.720 -0.77%
Dec 11, 2024 899.640 899.640 899.640 899.640 -0.87%
Dec 10, 2024 907.520 907.520 907.520 907.520 -0.72%
Dec 09, 2024 914.070 914.070 914.070 914.070 0.51%
Dec 06, 2024 909.430 909.430 909.430 909.430 -0.08%
Dec 05, 2024 910.130 910.130 910.130 910.130 -0.17%
Dec 04, 2024 911.720 911.720 911.720 911.720 -0.88%
Dec 03, 2024 919.790 919.790 919.790 919.790 -0.53%
Dec 02, 2024 924.650 924.650 924.650 924.650 -0.51%
Nov 29, 2024 929.360 929.360 929.360 929.360 0.28%
Nov 27, 2024 926.720 926.720 926.720 926.720 0.82%
Nov 26, 2024 919.150 919.150 919.150 919.150 -0.87%
Nov 25, 2024 927.230 927.230 927.230 927.230 1.61%
Highest: 929.360 Lowest: 845.650 Difference: 83.710 Average: 901.946 Change %: -6.112
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

0P0000M0RR Comments

Write your thoughts about Pictet-biotech I Dy Gbp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email